SHAREHOLDER ALERT: L & K Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Spe...
October 23 2015 - 3:25PM
Business Wire
Levi & Korsinsky, LLP announces that it has commenced an
investigation of Spectrum Pharmaceuticals, Inc. (“Spectrum
Pharmaceuticals” or the “Company”) (NASDAQGS: SPPI) concerning
possible violations of federal securities laws by the Company
and/or certain of its officers and directors.
On October 23, 2015, Spectrum announced that it has received a
Complete Response Letter from the U.S. Food and Drug Administration
(FDA) in response to its New Drug Application seeking clearance for
Evomela, indicating that the FDA cannot approve the application in
its present form. Upon this news, shares of Spectrum
Pharmaceuticals fell more than 20% on intraday trading. To obtain
additional information about the investigation, go to:
http://zlk.9nl.com/spectrum
or contact Joseph E. Levi, Esq. either via email at
jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877)
363-5972.
Levi & Korsinsky is a national firm with offices in New
York, New Jersey, Connecticut and Washington D.C. The firm’s
attorneys have extensive expertise in prosecuting securities
litigation involving financial fraud, representing investors
throughout the nation in securities and shareholder lawsuits.
Attorney advertising. Prior results do not guarantee similar
outcomes.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151023005883/en/
Levi & Korsinsky, LLPJoseph E. Levi, Esq.Tel:
212-363-7500Toll Free: 877-363-5972Fax: 212-363-7171www.zlk.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024